Email
Print
Mycobacterium Infections Treatment Market are a class of multisystem
infections caused by a pathogen called mycobacteriaceae. Mycobacterial
infections are largely asymptomatic in nature, however, as per the strain and
body composition the effects are fatal and can propel hospitalizations in those
with the compromised immune system. However, some of the pre-approved medicines
utilized for treating the condition are clarithromycin, azithromycin and rifampin,
amongst others. Additionally, research and development activities partaken by
key players along with climate change subjugating the cases of bacterial spread
will allow the Market to grow at a CAGR of 5.6% during the forecast period of
2022-2027, to garner a market size equivalent to $20.2 billion by 2027.
Mycobacterium Infection Treatment Drivers
A Substantial Presence of Tuberculosis Cases across
Developing Countries along with Effective Treatment Propositions in Developed
Nations have Proliferated the Market Demand.
As per the WHO, nearly 95% of TB cases and deaths occur in
developing countries. Moreover, the substantial presence of HIV cases in
countries and regions such as Africa has propelled the market demand, as people
who are infected with HIV are 18 times more likely to develop active TB. People
with undernutrition are 3 times more at risk. Globally in 2020, there were 1.9
million new TB cases that were attributable to undernutrition. Additionally,
owing to advanced healthcare systems in developed countries, the detection and
correct treatment has proliferated the market demand.
A Robust Growth in the Prevalence of NTM along with
Strong Research and Development Activities Monitored by Agency such as the WHO
has Proliferated Market Demand.
The number of patients treated with NTM diseases worldwide
has risen dramatically over the past three decades. Recent estimates from
Breathe 2022, suggest an incidence of up to 14.1 cases per 100,000 worldwide,
thereby curating positive affluence over the treatments market. Critically,
research highlights a strong correlation between the incidence of NTM and
climate change, leading to an increased Tropics area. Lastly, strong monitoring
of prepositions by the WHO has aided in the strong market growth in the market.
Clinical
Trial and Product Approval
In
October 202, Microbion Corporation announced the positive effects of pravibismane
on bacterial energetics in Pseudomonas aeruginosa, Staphylococcus
aureus, Escherichia coli and Mycobacterium avium species.
In September 2022, FDA approved Oxford Immunotec’s T-Cell Select Reagent Kit to
automate the workflow of T-Sport TB.
Major
Players in the Market Include
The
Major Players in the Mycobacterium Infections Treatment Market Include Insmed
Incorporated, Red Hill Biopharma, Novartis, Savara, Beyond Air, Sanofi,
Novartis AG, CMP Pharma and Cipla.
Over the years, key company focus has shifted to finding alternative treatment ways for tackling the growing cases of multidrug-resistant TB amongst other priorities for clinical research.
To request for a quote, provide your details in the below link:
https://www.industryarc.com/reports/request-quote?id=17407
Media Contact: